Last Friday, corporate raider Carl Icahn asked Clorox
On Monday, Clorox announced that its board had unanimously rejected Icahn's unsolicited bid to acquire the company. The board believes the bid substantially undervalues Clorox and that the company's own strategic plan is in the best interests of shareholders.
The deal itself had drawn some skepticism after Icahn suggested that competitors such as Procter & Gamble
Then on Wednesday, Icahn upped the ante, offering to pay $80 per share, a bid that the company said it would consider in due course.
No means no, mister
In addition, Clorox has also adopted a shareholder rights agreement, also known as a "poison pill," to protect itself from future unwanted advances. This agreement would end up significantly penalizing any person or group that acquires 10% or more of outstanding shares without board approval, by giving all other shareholders the right to buy more shares at a substantial discount. This usually makes it prohibitively expensive for any potential suitors to proceed without board approval. Icahn now has a claim on 9.37% of outstanding shares, according to Capital IQ.
Poison pills typically aren't shareholder-friendly, although they can be in some instances. You just have to trust that the board and management are fulfilling their fiduciary duties to the shareholders and aren't putting their interests first.
Fool contributor Evan Niu hates the smell of bleach and doesn't own shares of any company mentioned. The Motley Fool owns shares of Clorox. Motley Fool newsletter services have recommended buying shares of Clorox, Procter & Gamble, and Kimberly-Clark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.